News
April 7, 2020
Member companies of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working with our partners in government and the pharmaceutical supply chain to mitigate shortages of medicines used in Canada’s hospitals due to increases in demand resulting from the COVID-19 outbreak.
April 1, 2020
The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.
March 18, 2020
The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.
March 11, 2020
The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada, on COVID-19: “The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working closely with Health Canada and our member companies to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.